BiotechTube

galantamine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

— → May 1, 2003

NCT ID
NCT00035204

About galantamine

galantamine is a approved stage product being developed by Johnson & Johnson for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00035204. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT00035204ApprovedCompleted
NCT00309725Phase 3Completed
NCT00035191Phase 3Completed
NCT00304629Phase 3Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85
acetaminophen extended release capletsApproved
85